Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023 08:00 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
August 24, 2023 08:30 ET
|
Verrica Pharmaceuticals Inc.
YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children ...
Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum
August 23, 2023 07:30 ET
|
Verrica Pharmaceuticals Inc.
Verrica’s product YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States,...
Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting
August 10, 2023 16:05 ET
|
Verrica Pharmaceuticals Inc.
Presentation highlights the antitumor response of VP-315 for the non-surgical treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance There are...
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 08, 2023 07:30 ET
|
Verrica Pharmaceuticals Inc.
– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children – ...
Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting
August 03, 2023 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
July 26, 2023 16:05 ET
|
Verrica Pharmaceuticals Inc.
– Verrica received $50M upon the close of the transaction; $75M of additional capital available in tranches based on the achievement of certain revenue milestones – – Proceeds from the transaction to...
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET
July 24, 2023 07:00 ET
|
Verrica Pharmaceuticals Inc.
Term loan facility would provide for up to $125M in non-dilutive capital; $50M immediately available to Company following close of the transaction, which is expected to occur by the end of this week...
Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum
July 21, 2023 16:24 ET
|
Verrica Pharmaceuticals Inc.
– Molluscum, is a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children – – YCANTH™ is a drug-device combination product...
Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York
May 31, 2023 07:00 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...